MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jjco/hyaa069

Медицинская библиотека · Japanese journal of clinical oncology · 2020

Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.

Nakamura Akifumi, Kondo Nobuyuki, Nakamichi Toru, Kuroda Ayumi, Hashimoto Masaki, Matsumoto Seiji, Yokoi Takashi, Kuribayashi Kozo, Kijima Takashi, Hasegawa Seiki

Оценочное исследованиеСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Limited options exist for treating post-recurrence patients with malignant pleural mesothelioma (MPM). This study aimed to evaluate the efficacy and feasibility of nivolumab in patients with post-operative recurrence of MPM in a real-world setting.

METHODS

This study included 35 patients with post-operative recurrence of MPM. Treatment consisted of 240-mg intravenous nivolumab administration every 2 weeks until progressive disease (PD) or serious adverse events (AEs). Additional post-treatment data were evaluated, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), post-treatment survival and AEs. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors. Survival analysis was performed using the Kaplan-Meier method. The feasibility analysis including AEs was performed with the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

RESULTS

Of the 35 patients who received nivolumab, median follow-up was 6 months. The median treatment duration was 3 months (range: 1-14 months), and median of 8 cycles (range: 2-32 cycles) was administered. Best overall responses were follows: 1 patient had complete response, 6 had partial response, 18 had stable disease and 8 had PD. The ORR was 20.0%, and the DCR was 77.1%. The median overall survival and PFS were 13.1 and 4.4 months, respectively. There were grade-3 AEs in four patients (11.4%). No grade-4 or -5 AEs were observed.

CONCLUSION

Nivolumab treatment in patients with post-operative recurrence of MPM seems safe and clinical efficacy.

Для цитирования: Nakamura Akifumi, Kondo Nobuyuki, Nakamichi Toru, Kuroda Ayumi, Hashimoto Masaki, Matsumoto Seiji, Yokoi Takashi, Kuribayashi Kozo, Kijima Takashi, Hasegawa Seiki. Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.. Japanese journal of clinical oncology. 2020. DOI: 10.1093/jjco/hyaa069.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.